Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 14166-28-0 | MDL No. : | MFCD11046554 |
Formula : | C9H10O3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | LQOPXMZSGSTGMF-RNGGSSJXSA-N |
M.W : | 166.17 | Pubchem ID : | 10535053 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.78 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 40.52 |
TPSA : | 43.37 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.4 cm/s |
Log Po/w (iLOGP) : | 1.44 |
Log Po/w (XLOGP3) : | 1.29 |
Log Po/w (WLOGP) : | 0.73 |
Log Po/w (MLOGP) : | 1.71 |
Log Po/w (SILICOS-IT) : | 1.38 |
Consensus Log Po/w : | 1.31 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.68 |
Solubility : | 3.45 mg/ml ; 0.0208 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.8 |
Solubility : | 2.63 mg/ml ; 0.0158 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -0.96 |
Solubility : | 18.3 mg/ml ; 0.11 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 2.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 3.03 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
182 g | With hydrogen In toluene | 200 g of the compound obtained in the above (2) and 1.5 L of toluene were mixed, heated and completely dissolved, and then charged into a 4 L high-pressure reactor. 10 g of the Pd / Pt catalyst was introduced into the high-pressure reactor, and hydrogen was introduced at 10 bar and purged for 5 minutes. After purging, hydrogen was injected at 12 bar and hydrogenated at 160 and 20 bar. The reaction was maintained for 70 minutes and then the catalyst was removed. The catalyst was separated into 5 L of hexane, followed by filtration and drying to obtain 182 g of a white compound (4). The obtained compounds were identified by NMR (1H and 13C) (JEOL, JNM-LA400) and IR (AVATAR, 360 FT-IR). The results are shown in FIGS. 4 and 5, respectively. |
182 g | With hydrogen In toluene at 160℃; for 1.16667 h; | 200 g of the compound obtained in the above (2) and 1.5 L of toluene were mixed, heated and completely dissolved, and then charged into a 4 L high-pressure reactor.In the high-pressure reactor In the Pd / Pt catalyst 10 g was charged with hydrogen to 10 bar and then purged (purge) 5 minutes.After purging, hydrogen was injected at 12 bar and heated to 160 ° C,The hydrogenation reaction was carried out at 20 bar.The reaction was maintained for 70 minutes and then the catalyst was removed. The catalyst was separated into 5 L of hexane, followed by filtration and drying to obtain 182 g of a white compound (4). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
76% | With sodium hydroxide In water at 70℃; for 0.166667 h; | (Example 16) To 10.0 g of norbornane-2,3-dicarboxylic anhydride (exo stereoisomeric ratio for the general formula (2) type = 50percent) were added 33.8 g of water and 16.0 g of a 30 wtpercent aqueous solution of sodium hydroxide (1.0 equivalents relative to the norbornane-2,3-dicarboxylic anhydride mixture), and the mixture was stirred at 70°C for 10 minutes. The solid was then separated by filtration and dried. The obtained solid was 4.62 g (exo stereoisomeric ratio for the general formula (2) type = 88percent).; (Example 17) With the exception of adding 48.9 g of water, preparation was conducted in the same manner as the example 16. The obtained solid was 2.42 g (exo stereoisomeric ratio for the general formula (2) type = 91 percent).; (Example 18) With the exceptions of using 41.6 g of water and 12.0 g of the 30 wtpercent aqueous solution of sodium hydroxide (0.75 equivalents relative to the norbornane-2,3-dicarboxylic anhydride mixture), preparation was conducted in the same manner as the example 16. The obtained solid was 1.84 g (exo stereoisomeric ratio for the general formula (2) type = 88percent).; (Example 19) With the exceptions of using 38.8 g of water and 16.0 g of the 30 wtpercent aqueous solution of sodium hydroxide (1.0 equivalents relative to the norbornane-2,3-dicarboxylic anhydride mixture), preparation was conducted in the same manner as the example 16. The obtained solid was 4.01 g (exo stereoisomeric ratio for the general formula (2) type = 88percent).; (Example 20) With the exceptions of using 33.2 g of water and 24.1 g of the 30 wtpercent aqueous solution of sodium hydroxide (1.5 equivalents relative to the norbornane-2,3-dicarboxylic anhydride mixture), preparation was conducted in the same manner as the example 16. The obtained solid was 6.91 g (exo stereoisomeric ratio for the general formula (2) type = 83percent). Furthermore, the filtrate exhibited an endo stereoisomeric ratio for the general formula (2) type = 83percent.; (Example 21) With the exceptions of using 27.6 g of water and 32.2 g of the 30 wtpercent aqueous solution of sodium hydroxide (2.0 equivalents relative to the norbornane-2,3-dicarboxylic anhydride mixture), preparation was conducted in the same manner as the example 16. The obtained solid was 9.24 g (exo stereoisomeric ratio for the general formula (2) type = 76percent). Furthermore, the filtrate exhibited an endo stereoisomeric ratio for the general formula (2) type = 90percent.; (Example 22) With the exceptions of using 21.6 g of water and 12.0 g of the 30 wtpercent aqueous solution of sodium hydroxide (0.75 equivalents relative to the norbornane-2,3-dicarboxylic anhydride mixture), preparation was conducted in the same manner as the example 16. The obtained solid was 5.39 g (exo stereoisomeric ratio for the general formula (2) type = 85percent). Furthermore, the filtrate exhibited an endo stereoisomeric ratio for the general formula (2) type = 76percent.; (Example 23) With the exceptions of using 18.8 g of water and 16.1 g of the 30 wtpercent aqueous solution of sodium hydroxide (1.0 equivalents relative to the norbornane-2,3-dicarboxylic anhydride mixture), preparation was conducted in the same manner as the example 16. The obtained solid was 7.61 g (exo stereoisomeric ratio for the general formula (2) type = 81 percent). Furthermore, the filtrate exhibited an endo stereoisomeric ratio for the general formula (2) type = 83percent. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
50% | With hydrogen In tetrahydrofuran | 5-norbornene-endo-2,3-dicarboxylic anhydride and 5-norbornene-exo-2,3-dicarboxylic anhydride were mixed together, tetrahydrofuran was added to the resulting mixture, and a hydrogenation was conducted under a hydrogen atmosphere using 5percent palladium-carbon as a catalyst. The hydrogenation rate was 100percent. Following completion of the hydrogenation reaction, the product was filtered and dried. The resulting powdered mixture of norbornane-endo-2,3-dicarboxylic anhydride and norbornane-exo-2,3-dicarboxylic anhydride (exo stereoisomeric ratio for the general formula (2) type = 50percent) was used as the test material |
[ 4100-80-5 ]
3-Methyldihydrofuran-2,5-dione
Similarity: 0.90
[ 5617-74-3 ]
3-Oxabicyclo[3.1.0]hexane-2,4-dione
Similarity: 0.88
[ 67911-21-1 ]
6,6-Dimethyl-3-oxabicyclo[3.1.0]hexane-2,4-dione
Similarity: 0.85
[ 185815-59-2 ]
4-Isobutyldihydro-2H-pyran-2,6(3H)-dione
Similarity: 0.81
[ 104802-52-0 ]
trans-Ethyl 4-(hydroxymethyl)cyclohexanecarboxylate
Similarity: 0.90
[ 166412-78-8 ]
Bis(7-methyloctyl) cyclohexane-1,2-dicarboxylate
Similarity: 0.90
[ 70969-58-3 ]
Diisobutyl cyclohexane-1,2-dicarboxylate
Similarity: 0.90
[ 4100-80-5 ]
3-Methyldihydrofuran-2,5-dione
Similarity: 0.90
[ 2611-02-1 ]
Cyclohexylmethyl cyclohexanecarboxylate
Similarity: 0.90
[ 4100-80-5 ]
3-Methyldihydrofuran-2,5-dione
Similarity: 0.90
[ 5617-74-3 ]
3-Oxabicyclo[3.1.0]hexane-2,4-dione
Similarity: 0.88
[ 1679-47-6 ]
3-Methyldihydrofuran-2(3H)-one
Similarity: 0.87
[ 63095-51-2 ]
(R)-4-Propyldihydrofuran-2(3H)-one
Similarity: 0.87
[ 5617-74-3 ]
3-Oxabicyclo[3.1.0]hexane-2,4-dione
Similarity: 0.88
[ 67911-21-1 ]
6,6-Dimethyl-3-oxabicyclo[3.1.0]hexane-2,4-dione
Similarity: 0.85
[ 335599-07-0 ]
Ethyl 3-oxa-bicyclo[3.1.0]hexane-6-carboxylate
Similarity: 0.85
[ 41088-52-2 ]
Methyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate
Similarity: 0.79
[ 3130-19-6 ]
Bis(7-oxabicyclo[4.1.0]heptan-3-ylmethyl) adipate
Similarity: 0.79